A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
Recruiting
Observational Study
HCC - Hepatocellular Carcinoma
TACE(Transcatheter Arterial Chemoembolization)
CT
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Observational
- Participants needed
- 121 (estimated)
- Sponsor
- Zhongda Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
By comparing the diagnostic accuracy of spectral CT and conventional CT in evaluating treatment response efficacy after TACE, this study aims to investigate the diagnostic performance of spectral CT in assessing treatment response following TACE for hepatocellular carcinoma.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. age 18-75 years;
2. diagnosis of HCC based on pathological findings or accepted clinical and imaging criteria;
3. Barcelona Clinic Liver Cancer (BCLC) stage A or B;
4. prior treatment with TACE;
5. undergoing contrast-enhanced spectral CT at 4-8 weeks after TACE;
6. undergoin…
Contacts